Kymera Therapeutics receives US FDA Fast Track Designation for KT-621, an oral STAT6 degrader to treat atopic dermatitis: Watertown, Massachusetts Saturday, December 13, 2025, 18: ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Denmark: A new systematic review and meta-analysis has shed light on how effectively biologic therapies can help restore the ...

GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines ...

GSK wins FDA approval for Blujepa, a new oral antibiotic treatment option for uncomplicated urogenital gonorrhea.

GlaxoSmithKline ( ($GB:GSK) ) has shared an update. GSK has announced that the European Medicines Agency’s Committee for Medicinal Products for ...

Celltrion receives US FDA approval of 300mg strength of Omlyclo, the first and only interchangeable biosimilar to Xolair: Incheon, South Korea Thursday, December 4, 2025, 11:00 Hr ...

Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase ...

Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 ...

Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable ...